Brendan Teehan - Nov 17, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP, COO, HEAD OF COMMERCIAL
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol: ACAD
Transactions as of: Nov 17, 2024
Transactions value $: -$173,630
Form type: 4
Date filed: 11/19/2024, 08:43 PM
Previous filing: Aug 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+9.91K	+18.84%		62.5K	Nov 17, 2024	Direct	F1, F2
transaction	ACAD	Common Stock	Options Exercise		+9.91K	+15.86%		72.4K	Nov 17, 2024	Direct	F1
transaction	ACAD	Common Stock	Sale	-$174K	-10.3K	-14.26%	$16.81	62.1K	Nov 19, 2024	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-9.91K	-50%	$0.00	9.91K	Nov 17, 2024	Common Stock	9.91K		Direct	F1, F5
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-9.91K	-50%	$0.00	9.91K	Nov 17, 2024	Common Stock	9.91K		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Brendan Teehan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan.
F3	The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
F6	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.